Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of "Buy" by Analysts

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) has earned an average rating of "Buy" from the eleven brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $95.25.

Several brokerages recently commented on JANX. Wedbush reaffirmed an "outperform" rating and set a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Scotiabank dropped their price objective on Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating for the company in a report on Friday, February 28th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd.

Janux Therapeutics Stock Down 0.5%

Shares of NASDAQ:JANX opened at $24.17 on Tuesday. The company has a market cap of $1.43 billion, a P/E ratio of -20.66 and a beta of 3.24. The business has a fifty day simple moving average of $28.50 and a 200-day simple moving average of $40.33. Janux Therapeutics has a 52 week low of $22.48 and a 52 week high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.05. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Sell-side analysts expect that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Insider Buying and Selling at Janux Therapeutics

In other Janux Therapeutics news, Director Ra Capital Management, L.P. acquired 341,742 shares of the firm's stock in a transaction on Wednesday, March 5th. The stock was purchased at an average price of $30.64 per share, with a total value of $10,470,974.88. Following the completion of the acquisition, the director now directly owns 9,658,988 shares in the company, valued at $295,951,392.32. This trade represents a 3.67% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Andrew Hollman Meyer sold 3,334 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10. Following the sale, the insider now owns 82,139 shares of the company's stock, valued at approximately $2,640,768.85. The trade was a 3.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 10,001 shares of company stock valued at $313,964 over the last three months. 8.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its stake in shares of Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after purchasing an additional 442 shares during the period. Avanza Fonder AB grew its holdings in Janux Therapeutics by 17.0% in the 1st quarter. Avanza Fonder AB now owns 3,049 shares of the company's stock worth $86,000 after buying an additional 444 shares in the last quarter. New York State Common Retirement Fund grew its holdings in Janux Therapeutics by 3.0% in the 1st quarter. New York State Common Retirement Fund now owns 16,435 shares of the company's stock worth $444,000 after buying an additional 471 shares in the last quarter. Rhumbline Advisers increased its position in Janux Therapeutics by 1.6% in the 4th quarter. Rhumbline Advisers now owns 38,153 shares of the company's stock valued at $2,043,000 after acquiring an additional 599 shares during the period. Finally, Exchange Traded Concepts LLC raised its stake in Janux Therapeutics by 20.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company's stock valued at $109,000 after acquiring an additional 686 shares in the last quarter. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.